Lack of Durable Cross-Neutralizing Antibodies against Zika Virus from Dengue Virus Infection

Matthew H. Collins, Eileen McGowan, Ramesh Jadi, Ellen Young, Cesar A. Lopez, Ralph S. Baric, Helen M. Lazear, Aravinda M. de Silva

Cross-reactive antibodies elicited by dengue virus (DENV) infection might affect Zika virus infection and confound serologic tests. Recent data demonstrate neutralization of Zika virus by monoclonal antibodies or human serum collected early after DENV infection. Whether this finding is true in late DENV convalescence (>6 months after infection) is unknown. We studied late convalescent serum samples from persons with prior DENV or Zika virus exposure. Despite extensive cross-reactivity in IgG binding, Zika virus neutralization was not observed among primary DENV infections. We observed low-frequency (23%) Zika virus cross-neutralization in repeat DENV infections. DENV-immune persons who had Zika virus as a secondary infection had distinct populations of antibodies that neutralized DENVs and Zika virus, as shown by DENV-reactive antibody depletion experiments. These data suggest that most DENV infections do not induce durable, high-level Zika virus cross-neutralizing antibodies. Zika virus–specific antibody populations develop after Zika virus infection irrespective of prior DENV immunity.

Zika virus is a member of the flavivirus family of arthropod-borne viruses, which includes West Nile virus, yellow fever virus, tick-borne encephalitis virus, and dengue virus (DENV) (1). The recent emergence of Zika virus in the Western Hemisphere caused widespread international concern. Although Zika virus infection is most commonly asymptomatic or causes only a mild, self-limited illness, recent epidemics have revealed new manifestations of Zika virus disease, including Guillain-Barré syndrome (2,3) and sexual transmission (4). Most alarmingly, and distinct from other flaviviruses, Zika virus infection during pregnancy can result in a spectrum of developmental abnormalities (congenital Zika syndrome) (5), which can include ocular damage, microcephaly, and fetal death (6). These manifestations raise public health challenges unique from those of other vectorborne diseases, particularly preventing sexual transmission and protecting pregnant women.

Given shared ecology and mosquito vectors, Zika virus is emerging in areas with endemic DENV transmission. In many areas of Latin America, most persons has been exposed to ≥1 natural DENV infections (7); in some regions, DENV vaccination has been implemented or is in clinical trials (8). Because there is known serologic cross-reactivity between Zika virus and DENV (9), determining how DENV immunity affects subsequent Zika virus infection is important.

The ability of flavivirus infection to induce antibodies that are virus-specific and that cross-react with different flaviviruses is well known (10–13), and flaviviruses have been grouped as serocomplexes on the basis of degree of antigenic overlap (11). Zika virus has not been studied extensively in this context; although it shares 54%–58% of its nucleotide sequence with the 4 serotypes of DENV in the envelope protein coding sequence (14), the extent to which Zika virus will group antigenically with the DENV serocomplex is unclear. Several groups recently reported that antibodies isolated from persons with prior DENV infections cross-neutralize Zika virus and cross-protect in animal models of Zika virus infection (15–19). These results raise the possibility of DENV infections or vaccines cross-neutralizing Zika virus and cross-protect against Zika virus. Moreover, researchers have been concerned that the plaque/focus reduction neutralization test, the standard serologic assay for distinguishing different flavivirus serocomplexes, will be unable to differentiate Zika virus from DENV. During 2016 in North Carolina, USA, we studied whether persons exposed to DENV maintain cross-neutralizing antibodies to Zika virus.

Methods

Human Subjects and Immune Serum
Serum was collected from North Carolina residents who had probable or confirmed DENV or Zika virus infection on the basis of self-reported symptoms and travel to areas in which these viruses are endemic. Serum samples from this study were assigned consecutive and arbitrary identification numbers such as DT165. A subset of DENV immune serum was obtained from a reference panel distributed by the Pediatric Dengue Vaccine Initiative. Samples were tested by virus-capture ELISA, and DENV– or Zika virus–reactive serum was further characterized by neutralization assays on Vero cells. All donations were
collected in compliance with the Institutional Review Board of the University of North Carolina at Chapel Hill (protocol 08–0895).

Serum that had neutralizing antibodies to 1 DENV serotype or to Zika virus with minimal cross-neutralizing antibodies were defined as primary flavivirus infections (meaning that the 50% inhibitory concentration [IC\textsubscript{50}] for a single DENV serotype or Zika virus was ≥4-fold higher than for any other virus tested). In most cases, the person’s travel history corroborated the primary immune status. Serum that had high levels of neutralizing antibody to ≥2 flaviviruses were defined as secondary (repeat) flavivirus infections. Most secondary infection samples were from persons who had resided in DENV- or Zika virus–endemic countries for ≥5 years.

Viruses and Cells

Zika Virus Stocks
The MR766 and Dakar 41519 strains of Zika virus were obtained from R. Tesh (World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA) (20,21). The Centers for Disease Control and Prevention (Atlanta, GA, USA) provided Zika virus strains H/PF/2013 and PRV-ABC59 (22,23).

DENV Stocks
All in vitro assays were conducted with the DENV World Health Organization reference strains: DENV-1 West Pac 74, DENV-2 S-16803, DENV-3 CH54389, and DENV-4 TVP-360 (initially obtained from R. Putnak, Walter Reed Army Institute of Research, Silver Spring, MD, USA). Virus stocks were prepared in C6/36 Aedes albopictus mosquito cells (ATCC no. CRL-1660) or Vero Cercopithecus aethiops monkey cells (ATCC no. CCL-81). C6/36 cells were grown at 32°C with 5% CO\textsubscript{2} in minimum essential medium supplemented with 10% fetal bovine serum (FBS), L-glutamine, nonessential amino acids, and HEPES (2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer. Vero cells were grown at 37°C with 5% CO\textsubscript{2} in Dulbecco modified Eagle medium supplemented with 5% FBS and L-glutamine. Virus stocks were titrated on Vero cells by plaque assay or focus-forming assay (24). Infected cell foci were detected at 40–48 h after infection, after fixation with 1%–2% paraformaldehyde and incubation with 500 ng/mL of flavivirus cross-reactive mouse monoclonal antibody (mAb) E60 (25), 2H2 (26), and/or 4G2 (26). After incubation with a 1:2,000 dilution of horseradish peroxidase–conjugated goat anti-mouse IgG (Sigma, St. Louis, MO, USA), foci were detected by addition of TrueBlue substrate (KPL). We analyzed foci with a CTL Immunospot instrument (CTL, Cleveland, OH, USA). All studies were conducted under biosafety level 2 containment.

ELISA
We measured binding of human serum IgG to DENV or Zika virus by ELISA as previously described (27). In brief, DENV virions were captured by the anti-E protein mouse mAb 4G2, blocked with 3% normal goat serum (GIBCO Life Technologies, Carlsbad, CA, USA) or 3% nonfat dairy milk (LabScientific, Inc., Highlands, NJ, USA), and incubated with human serum at indicated dilutions at 37°C for 1 h, and binding was detected with an alkaline phosphatase–conjugated antihuman secondary antibody (Sigma) and p-nitrophenyl phosphate substrate (Sigma). Absorbance at 405 nm was measured on an Epoch plate reader (BioTek, Suwanee, GA, USA). ELISAs used to confirm depletion were performed as given earlier, with the exception that 50 ng purified DENV was coated directly to the plate at 37°C for 1 h at 1:50 dilution before serum was tested. ELISA data are reported as optical density values that are the average of technical replicates, unless otherwise indicated. The average optical density for technical replicates using naive human serum at the same dilution factor as test samples serves as the negative control in ELISAs. In depletion experiments, the OD of depleted sample is expressed as percentage of control from same serum for some graphs as indicated.

Neutralization Assays
We adapted the previously described focus-reduction neutralization test (FRNT) (28) to a 96-well format (18). Neutralization titers were determined by FRNT by serial 3-fold dilution of human serum and mixing with ≈50–100 focus-forming units of virus in Dulbecco modified Eagle medium with 2% FBS. The virus–antibody mixtures were incubated for 1 h at 37°C and then transferred to a monolayer of Vero cells for titration by focus assay as described earlier. For neutralization assays, we calculated IC\textsubscript{50} values by using the sigmoidal dose response (variable slope) equation of Prism 6 (GraphPad Software, San Diego, CA, USA). One set of DENV-1–4 neutralization values (DT003) was determined previously by U937 flow-based assay (29), but Zika virus neutralization was determined by Vero FRNT. IC\textsubscript{50} values shown for certain Zika virus-immune serum samples were determined on 24-well plaque assay (30) (Table 1). Reported values were required to have an R\textsuperscript{2} >0.75, a hill slope >0.5, and an IC\textsubscript{50} within the range of the assay.

Depletions
As previously described (31), purified viral antigen for depletions was obtained by infecting Vero cell cultures in 850 cm\textsuperscript{2} roller bottles (Greiner Bio-One, Monroe, NC, USA) with DENV and then concentrating DENV-containing supernatants at 4°C by tangential flow ultrafiltration using the Pellicon mini system with a 100-kD cutoff membrane (Pellicon-2 mini Holder and Pellicon-2 Mini Filters; Millipore, Darmstadt, Germany). The flow rate was 400 mL/min, and
filtration rate was ≈100 mL/min; pressure was 20–30 psi. Concentrated virus was then purified on a 15%–65% sucrose gradient by ultracentrifugation (SW 40 Ti, Beckman Coulter, Brea, CA, USA) at 21,583 relative centrifugal force for 18 h at 4°C. The fractions with maximal content of virus was determined by resolving fractions by SDS-PAGE and protein concentration was measured by Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA).

Purified viral antigen was conjugated to Polybeads polystyrene 4.5-µm microspheres (PolyScience, Niles, IL, USA) in accordance with the manufacturer’s instructions (100 µg/250 µL beads) by incubating overnight at room temperature. Control beads were incubated with equal amount of bovine serum albumin. Beads were blocked with 10 mg/mL bovine serum albumin, washed 3 times with 0.1 M borate buffer (pH 8.5), followed by 3 times with phosphate buffered saline. For depletion, serum was diluted 1:10 in phosphate buffered saline and incubated with 100 µg DENV-1 + 100 µg DENV-2 divided over 3 rounds at 37°C for 1 h each. After incubation, tubes were centrifuged at 20,800 relative centrifugal force to pellet beads with bound antibodies, and serum was pipetted off the undisturbed pellet and transferred to new vials. We confirmed depletion efficacy with direct binding ELISA. Serum with higher titers of binding antibodies was subjected to additional rounds of depletion until IgG binding was reduced to background levels.

### Table 1. DENV or Zika virus neutralization profiles for persons with travel history to Zika virus–endemic areas*

| Serostatus, serum sample ID | Place of Infection | IC_{50} † | DENV-1 | DENV-2 | DENV-3 | DENV-4 | Zika virus |
|----------------------------|-------------------|----------|--------|--------|--------|--------|-----------|
| **Primary DENV-1**         |                   |          |        |        |        |        |           |
| 147                        | Latin America     |          | 3,552  | 287    | 557    | 75     | <20       |
| 153                        | Latin America     |          | 757    | <20    | <20    | <20    | <20       |
| 05/262                     | Asia              |          | 274    | <20    | <20    | <20    | <20       |
| 06/125                     | Asia              |          | 3,823  | 222    | 125    | 80     | <20       |
| 99/1230                    | Asia              |          | 1,219  | 63     | 30     | 24     | <20       |
| **Primary DENV-2**         |                   |          |        |        |        |        |           |
| 001                        | Asia              |          | 49     | 2,188  | 48     | 89     | <20       |
| 08/90                      | Asia              |          | <20    | 2,966  | <20    | <20    | <20       |
| 08/91                      | Asia              |          | <20    | 838    | <20    | <20    | <20       |
| 09/165                     | Asia              |          | <20    | 2,093  | <20    | <20    | <20       |
| 09/251                     | Asia              |          | <20    | 417    | <20    | <20    | <20       |
| **Primary DENV-3**         |                   |          |        |        |        |        |           |
| 116                        | Asia              |          | 200    | 979    | 5,342  | 290    | <20       |
| 118                        | Latin America     |          | 173    | 374    | 3,041  | 56     | <20       |
| 125                        | Latin America     |          | 99     | 97     | 1,648  | 35     | <20       |
| 133                        | Latin America     |          | 89     | 171    | 3,348  | 83     |            |
| 06/297                     | Asia              |          | 27     | <20    | 573    | <20    | <20       |
| **Primary DENV-4**         |                   |          |        |        |        |        |           |
| 112                        | Latin America     |          | 908    | 1367   | 591    | 18,408 | <20       |
| 06/105                     | Asia              |          | <20    | <20    | <20    | 941    | <20       |
| 06/302                     | Asia              |          | <20    | <20    | <20    | 4,130  | <20       |
| 09/159                     | Asia              |          | 115    | 226    | 478    | 5,694  | <20       |
| **Primary Zika virus**     |                   |          |        |        |        |        |           |
| 168                        | Latin America     |          | 36†    | <20    | 78‡    | <20    | 1,382     |
| 172                        | Latin America     |          | <20    | <20    | <20    | 8,468  |           |
| **Secondary DENV**         |                   |          |        |        |        |        |           |
| 000                        | Asia              |          | 3,306  | 2,087  | 1,162  | 782    | <20       |
| 003                        | Asia              |          | 556    | 178    | 299    | <20    | 146       |
| 115                        | Asia              |          | 100    | 355    | 830    | 245    | <20       |
| 141                        | Latin America     |          | 1,902  | 1,953  | 4,530  | 664    | <20       |
| 144                        | Asia              |          | 155    | 191    | 5,782  | 1,612  | 699       |
| 145                        | Asia              |          | 601    | 1,262  | 240    | 60     | <20       |
| 146                        | Asia              |          | 403    | 1,052  | 1,480  | 451    | 28        |
| 155                        | Asia              |          | 215    | 299    | 71     | 27     | <20       |
| 160                        | Latin America     |          | 947    | 3,564  | 131    | 1,600  | <20       |
| 06/123                     | Asia              |          | 1,776  | 827    | 822    | 157    | <20       |
| 06/124                     | Asia              |          | 1,454  | 1,208  | 1,673  | 1,011  | <20       |
| 09/157                     | Asia              |          | 282    | 1,104  | 73     | 134    | <20       |
| 09/250                     | Asia              |          | 375    | 1475   | 151    | 94     | <20       |
| **Secondary Zika virus**   |                   |          |        |        |        |        |           |
| 165                        | Latin America     |          | 60‡    | 79‡    | 70‡    | 508    | 1655      |
| 166                        | Latin America     |          | 929    | 393    | 4344   | 240    | 1814      |

*DENV, dengue virus; IC_{50}, 50% inhibitory concentration; ID, identification.
†All neutralization testing performed on Vero cells with the exception of DT003, which was limiting and historic values performed on a U937 Flow-based assay are shown for DENV-1–4. Zika virus IC_{50} values for DT003 are from Vero assays.
‡Curves that did not pass quality metrics are marked. Such curves might signify very low titer IC_{50} values or variable background at the lower limit of detection in serum with no specific neutralization activity.
Results
To study human antibody interactions between DENV and Zika virus, we assembled 36 late convalescent serum samples from persons exposed to DENV, Zika virus, or both (Table 1). The panel comprised serum from 21 persons exposed to primary flavivirus infections (with each DENV serotype represented and 2 cases of Zika virus) and serum from 15 persons exposed to ≥2 flavivirus infections, including 2 persons exposed to both DENV and Zika virus.

We measured total IgG binding to DENV and Zika virus using a virus capture ELISA. We observed extensive cross-reactivity between DENV serotypes and between DENV and Zika virus, confirming that cross-reactive binding antibodies are maintained for many years after infection (Figure 1). Although cross-reactive binding antibodies are commonly detected in flavivirus-immune serum, neutralization assays are more specific and can distinguish even between different DENV serotypes (32). We therefore tested whether convalescent serum antibodies in persons exposed to DENV cross-neutralize Zika virus by a Vero cell–based neutralization assay. Serum from persons exposed to primary DENV infection of any serotype did not cross-neutralize Zika virus (Table 1; online Technical Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/23/5/16-1630-Techapp1.pdf). In contrast, Zika virus was readily neutralized by serum from persons who had traveled to Brazil (DT168) and Colombia (DT172) in 2015 and experienced acute illnesses consistent with an arbovirus infection. Both serum samples strongly neutralized Zika virus, showing low or no cross-neutralization of the 4 DENV serotypes (Table 1; online Technical Appendix Figure 1, panels C, D), consistent with primary Zika virus infection.

Persons exposed to secondary DENV infections develop broadly neutralizing antibodies that neutralize even DENV serotypes not encountered by that person (33). We determined the neutralization profile for 13 serum samples from persons with secondary DENV. Although the potency of neutralization varied, all but 1 (DT155) of the 13 samples had high levels of neutralizing activity (IC_{50} >100) against at least 3 DENV serotypes, and 7 were highly neutralizing against all 4 serotypes (Table 1). Despite this extensive cross-reactivity, most (10 [77%]) secondary DENV-immune serum samples failed to neutralize Zika virus (Table 1; online Technical Appendix Figure 1). Serum from 1 person showed low levels of cross-neutralizing activity (DT146), and 2 serum samples (DT003 and DT144) had high levels of Zika virus neutralizing antibodies. Two donors (DT165 and 166) reported suspected Zika virus infections acquired while in Brazil in 2015 during a known Zika virus outbreak. Serum from these 2 persons also neutralized Zika virus and ≥1 DENV serotypes, indicating that these most likely represent secondary Zika virus infections (online Technical Appendix, Figure 1, panels E, F). These results demonstrate that the broadly cross-neutralizing antibody response that is a hallmark of repeat DENV infections is mainly confined to the DENV serocomplex, although in some cases these antibodies also might cross-neutralize Zika virus.

Zika virus strains are divided into 2 genotypes, Asian and African; contemporary Zika virus isolates from Latin America are uniformly of the Asian genotype, consistent with the model that Zika virus spread from Southeast Asia.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 5, May 2017

Lack of Antibodies Against Zika Virus from DENV

To test the hypothesis that Zika virus infection elicits type-specific antibody, even in the presence of DENV immunity, we incubated serum with polystyrene beads coated with purified DENV antigen to remove DENV-specific and flavivirus cross-reactive antibody (Figure 2, Table 3). We then assessed binding of DENV using beads coated with DENV1 and DENV2 antigens. Serum was incubated with BSA were used as a control.

Table 2. Zika virus strains and neutralization in selected serum*

| Strain   | Genotype | Origin   | Year | Reference | DT168 | DT172 | DT165 | DT166 |
|----------|----------|----------|------|-----------|-------|-------|-------|-------|
| MR766    | African  | Uganda   | 1947 | (21)      | 2,546 | 2,898 | 1,918 | 3,890 |
| DAK41519 | African  | Senegal  | 1982 | (22)      | 700   | 1,186 | 547   | 1,203 |
| H/PF/2013| Asian    | Tahiti   | 2013 | (23)      | 609   | 531   | 516   | 469   |
| PRVABC59 | Asian    | Puerto Rico | 2015 | (24)      | 436   | 1,606 | Not tested | Not tested |

*IC<sub>50</sub>, 50% inhibitory concentration; ID, identification.

Table 3. 50% Inhibitory concentrations for serum in depletion experiments of DENV and Zika virus*

| Serum sample ID | DENV-2 | DENV-4 | Zika virus |
|----------------|--------|--------|------------|
| DT000 Control  | <20    | <20    | <20        |
| DT000 Depleted |        |        |            |
| DT001 Control  | 1,376  | 60     | <20        |
| DT001 Depleted | 331    | 24     | <20        |
| DT168 Control  | 83     | 48     | 1,978      |
| DT168 Depleted | <20    | <20    | 2,351      |
| DT172 Control  | 22     | 32     | 2,341      |
| DT172 Depleted | <20    | <20    | 2,046      |
| DT165 Control  | 198    | 162    | 3,067      |
| DT165 Depleted | 31     | 78     | 2,060      |
| DT166 Control  | 1,556  | 1,138  | 1,090      |
| DT166 Depleted | <20    | 126    | 873        |

*DENV, dengue virus; ID, identification.

Discussion

Because Zika virus is emerging in areas with high rates of dengue prevalence, the extent of antibody cross-reactivity to Oceania and from there to Brazil (34). To evaluate the effect of Zika virus strain variation on neutralization, we tested selected DENV and Zika virus–immune serum against 4 Zika virus strains representing diverse temporal and geographic origins (Table 2). All 4 strains exhibited similar neutralization patterns, specifically that they were neutralized by serum from primary (DT168 and DT172) or secondary (DT165 and DT166) Zika virus cases, but not by serum from a secondary DENV infection (DT145) (Table 2; online Technical Appendix Figures 2, 3), supporting the idea that Zika virus exists as a single serotype. Zika virus strain MR766 was relatively more susceptible than other strains to neutralization, and it was the only strain to exhibit low-level neutralization by secondary DENV serum (IC<sub>50</sub>, 67). In general, IC<sub>50</sub> titers were similar for primary Zika virus serum and for secondary Zika virus serum, consistent with the idea that cross-reactive antibodies from prior DENV infection do not contribute to Zika virus neutralization.

Figure 2. Schematic of the method used for depletion of human serum with DENV antigen to distinguish Zika virus–specific from cross-reactive flavivirus antibodies. Serum was incubated with DENV-1 and DENV-2 coated on polystyrene beads, enabling removal of DENV-specific and cross-reactive antibodies. DENV, dengue virus.
between these 2 viruses needs to be thoroughly evaluated. Recent studies have reported that DENV infection results in antibodies that cross-neutralize Zika virus \((15,16,18)\). Plasmablasts isolated from patients during or immediately after recovery from acute DENV infection produced antibodies that cross-neutralized Zika virus in cell culture \((35)\) and were protective in a mouse model of Zika virus infection \((18)\). Priyamvada et al. \((16)\) demonstrated moderate to high-titer Zika virus neutralization in serum from 9 DENV-infected persons; Zika virus neutralization activity was maintained out to 100 days of convalescence in 1 of the 5 persons with paired samples. They further reported that 7 of 47 mAbs derived from plasmablasts from 4 patients with acute DENV infection cross-neutralized Zika virus.

Our data do not demonstrate frequent and high-level cross-neutralization of Zika virus after exposure to DENV. Of 19 persons who had recovered from primary DENV infections, none showed cross-neutralization of Zika virus. Among persons exposed to repeat DENV infections, 3 (23%) of 13 showed Zika virus neutralizing antibodies. The remaining 10 persons had no detectable Zika virus neutralizing antibodies despite having high levels of neutralizing antibodies to multiple DENV serotypes. DT165 and 166 are classified as secondary Zika virus strains on the basis of neutralization profile, epidemiologic context (these donors had fever and rash illness while residing in northeastern Brazil in 2015 during peak Zika virus transmission), and the presence of Zika virus type–specific antibodies in their serum. Accordingly, these persons have high titers of neutralizing antibodies to Zika virus in addition to neutralization activity to \(\geq 1\) DENV serotypes. These results are consistent with those reported by Swanstrom et al., who found that only 1 of 16 persons exposed to repeat DENV infections had Zika virus \(IC_{50}\) values \(>1:100\) \((18)\). Low-level cross-neutralization to heterologous DENV serotypes is also observed into late convalescence after primary DENV infection; however, this phenomenon typically does not preclude accurate diagnosis of the originally infecting DENV serotype, nor does it confer immunity to secondary DENV infection by heterologous serotypes \((30,36)\).

A key feature of acute DENV infection is the transient induction of high levels of flavivirus cross-neutralizing and cross-protective antibody \((33)\). Over a few months, the neutralizing antibody response becomes more specific to \(\geq 1\) DENV serotypes, with little to no cross-neutralization of viruses belonging to other flavivirus serocomplexes \((33)\). Timing of sample collection probably explains high levels of DENV–Zika virus cross-neutralizing antibodies observed by only some groups. Barba-Spaeth et al. \((15)\) and Priyamvada et al. \((16)\) performed their studies with blood samples collected from patients a few days to weeks after recovery from acute DENV infection, when overall antibody response is known to be broadly cross-neutralizing. In contrast, our studies were performed with samples collected \(>6\) months after infection when the neutralizing antibody response has become more specific to the viruses responsible for infection.

Figure 3. Use of depletion of human serum with DENV antigen to distinguish Zika virus–specific from cross-reactive flavivirus antibodies. A) Depletion efficiency was determined by direct ELISA. Plates were coated with depleting antigens (DENV-1 and DENV-2) and binding of control and depleted serum was measured. B–E) Binding of depleted serum to Zika virus H/PF/2013 was measured by capture ELISA. BSA, bovine serum albumin; DENV, dengue virus; OD, optical density.
reliably predict functional outcomes, such as neutralization, enhancement, or protection, and our results suggest that most persons infected with DENVs do not maintain high levels of Zika virus neutralizing antibodies 6 months after DENV infection. Although Zika virus is genetically more closely related to the DENVs than to other flaviviruses, the long-lived antibody cross-neutralization within the DENV serocomplex does not extend to Zika virus in most of our cohort. Furthermore, our data indicate that a population of Zika virus–specific neutralizing antibodies develops after Zika virus infection, even in the presence of preexisting DENV immunity. The corollary is that cross-reactive antibodies and memory B cells from the prior DENV infection are not the major source of Zika virus neutralizing antibodies; rather, de novo priming of naive B cells by Zika elicits Zika type-specific antibody responses. Thus, we propose that Zika virus does not belong to the DENV serocomplex and that DENV-immune persons will remain susceptible to Zika virus infection. Moreover, live attenuated tetravalent DENV vaccines are being evaluated for safety and efficacy in Asia and Latin America. Our results indicate that DENV neutralizing antibody induced by these vaccines are unlikely to protect against Zika virus infection.

In the field, undifferentiated fever in the tropics can have a multitude of causes and often presents a diagnostic challenge (37). Molecular detection of Zika virus has good specificity but is not ideal for diagnosing it in persons who seek care many days after illness onset or have asymptomatic infection. Simple serologic assays based on binding antibody are difficult to interpret because of flavivirus cross-reactivity (9,10). This scenario, typified by DT144, 165, and 166, whereby flavivirus exposure history is uncertain with currently available assays (IgG or IgM ELISA), represents a critical challenge facing public health systems throughout the world.
the tropics where billions of persons are at risk for DENV and Zika virus infections (38). Our results suggest that the classical flavivirus plaque/focus reduction neutralization test might be reliable for determining previous Zika virus infection, particularly in the setting of retrospective serologic surveys and vaccine trials. We also note that the neutralization test is not reliable for testing samples collected during or soon after recovery from a DENV or Zika virus infection because of temporarily broad cross-neutralization and poor specificity. Indeed, US public health laboratories and others have reported on the poor specificity of testing for Zika virus in acute or early convalescent samples using currently available tests and algorithms (39–42). On the basis of our studies using samples collected at late convalescence, we propose that the neutralization assay might retain utility for supporting Zika virus and DENV vaccine and other clinical trials; population-level serosurveillance; and clinical management of some patients, such as pregnant women, when blood samples are collected many months after a suspected infection.

Interest and investigation are ongoing regarding whether Zika virus strain–dependent factors might explain phenomena observed during the current epidemic. Although a more comprehensive and in-depth analysis of Zika virus genetic variation might reveal viral determinants of pathogenesis, our experiments suggest that epitopes conferring susceptibility to neutralization by human serum have not changed substantially over time. We do find that the prototype Zika virus strain MR766 is more readily neutralized than other Zika virus strains. MR766 might provide the most sensitive screen for cross-neutralizing antibody, but relevance of such antibody should be confirmed by an isolate more representative of contemporary circulating viruses.

In conclusion, the current Zika virus epidemic presents many urgent challenges but also great opportunities to dramatically expand our knowledge of humoral immunity to flaviviruses. Although our results argue for infrequent cross-neutralization of Zika virus by DENV-immune serum and for development of independent populations of neutralizing antibody to these 2 viruses, additional and larger studies are needed to determine whether the rate of Zika virus cross-neutralization varies in different populations, particularly in DENV-endemic areas where ongoing subclinical exposure to DENV could further broaden the range of cross-neutralization in polyclonal serum. That effective vaccines have been developed against several flaviviruses is encouraging (43–46), but much remains to be learned about Zika virus–specific antibody responses and the dynamics of cross-reactive antibody in persons with multiple flavivirus exposures. Knowledge on these fronts will better inform Zika virus vaccine development, rational design of serodiagnostic tests, and general understanding of antibody responses to related viruses.

This study was supported by National Institutes of Health grants R01-AI107731 (to A.d.S.) and P01-AI106695 (subcontract to A.d.S.; principal investigator Eva Harris, University of California, Berkeley).

Dr. Collins is an infectious diseases physician at the University of North Carolina, Chapel Hill, North Carolina. His research interests include global health, emerging infections, and human antibody responses to medically important viruses.

References

1. Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol. 2016;90:4864–75. http://dx.doi.org/10.1128/JVI.00252-16
2. Smith DW, Mackenzie J. Zika virus and Guillain-Barré syndrome: another viral cause to add to the list. Lancet. 2016;387:1486–8. http://dx.doi.org/10.1016/S0140-6736(16)00564-X
3. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika virus infection complicated by Guillain-Barré syndrome—case report, French Polynesia, December 2013. Euro Surveill. 2014;19:20720. http://dx.doi.org/10.2807/1560-7917.ES2014.19.9.20720
4. Moreira J, Peixoto TM, Machado De Siqueira A, Lamas CC. Sexually acquired Zika virus: a systematic review. Clin Microbiol Infect. 2017 Jan 3 [Epub ahead of print]. pii: S1198-743X(16)30659-0. http://dx.doi.org/10.1016/j.cmi.2016.12.027
5. Miranda-Filho DB, Martelli CM, Ximenes RA, Araújo TV, Rocha MA, Ramos RC, et al. Initial description of the presumed congenital Zika syndrome. Am J Public Health. 2016;106:598–600. http://dx.doi.org/10.2105/AJPH.2016.303115
6. Coyne CB, Lazear HM. Zika virus—reigniting the TORCH. Nat Rev Microbiol. 2016;14:707–15. http://dx.doi.org/10.1038/nrmicro.2016.125
7. Castanhã PMS, Cordeiro MT, Martelli CM, Souza WV, Marques ET Jr, Braga C. Force of infection of dengue serotypes in a population-based study in the northeast of Brazil. Internat Med. 2013;141:1080–8. http://dx.doi.org/10.1016/j.sip.20090268812001367
8. World Health Organization. Dengue vaccine: WHO position paper—July 2016. Wkly Epidemiol Rec. 2016;91:349–64.
9. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lamb AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232–9. http://dx.doi.org/10.3201/eid1408.080287
10. Allwinn R, Doerr HW, Emmerich P, Schmitz H, Preiser W. Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol (Berl). 2002;190:199–202. http://dx.doi.org/10.1007/s002810101123
11. Mansfield KL, Horton DL, Li L, Barrett AD, Smith DJ, Johnson AJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92:2821–9. http://dx.doi.org/10.1099/vir.0.031641-0
12. Crill WD, Chang G-JJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78:13975–86. http://dx.doi.org/10.1128/JVI.78.24.13975-13986.2004
13. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5:e1188. Erratum in: PLoS Negl Trop Dis. 2011;5(8). http://dx.doi.org/10.1371/journal.pntd.0001188
14. Kostyuchenko VA, Lim EX, Zhang S, Fibransah G, Ng TS, Ooi JS, et al. Structure of the thermally stable Zika virus. Nature. 2016;533:425–8.
15. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Meditis I, Sharma A, et al. Structural basis of potent Zika–dengue
Lack of Antibodies Against Zika Virus from DENV

32. Maeda A, Maeda J. Review of diagnostic plaque reduction neutralization tests for flavivirus infection. Vet J. 2013;195:33–40. http://dx.doi.org/10.1016/j.tvjl.2012.08.019

33. Wahala WMPB, de Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3:2374–95. http://dx.doi.org/10.3390/v3122374

34. Faria NR, Azavedo RS, Kraemer MU, Souza R, Cunha MS, Hill SC, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352:345–9. http://dx.doi.org/10.1126/science.aaf5036

35. Dejnirattisai W, Wongwiwat V, Supasa S, Zhang X, Dai X, Rouvinski A, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170–7. http://dx.doi.org/10.1038/ni.3058

36. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis. 2015;211:590–9. http://dx.doi.org/10.1093/infdis/jiu481

37. Crump JA, Gove S, Parry CM. Management of adolescents and adults with febrile illness in resource limited areas. BMJ. 2011;343:d4847. http://dx.doi.org/10.1136/bmj.d4847

38. Bogoch II, Brady OJ, Kraemer MU, German M, Creatore MI, Brett S, et al. Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study. Lancet Infect Dis. 2016;16:1237–45. http://dx.doi.org/10.1016/S1473-3099(16)30270-5

39. Food and Drug Administration. FDA warns health care providers against relying solely on Zika virus serological IgM assay results; reminds them to wait for confirmatory test results before making patient management decisions [cited 2017 Jan 20]. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm534515.htm

40. Centers for Disease Control and Prevention. Guidance for US laboratories testing for Zika virus infection [cited 2017 Jan 22 ]. https://www.cdc.gov/zika/laboratories/lab-guidance.html

41. Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA, Rose L, et al.; MTS. Interim guidance for Interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep. 2016;65:543–6. http://dx.doi.org/10.15585/mmwr.mm6521e1

42. Landry ML, St George K. Laboratory diagnosis of Zika virus infection. Arch Pathol Lab Med. 2017;141:60–7. http://dx.doi.org/10.5858/arpa.2016-0406-SA

43. Wilder-Smith A, Gubler DJ. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science. 2015;350:626–7. http://dx.doi.org/10.1126/science.aaf5036

44. Paulke-Korinek M, Kollaritsch H, Kundi M, Zwai I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015;33:3600–4. http://dx.doi.org/10.1016/j.vaccine.2015.05.037

45. Wittermann C, Izu A, Petri E, Gniel D, Fragapane E. Five year immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2015;92:1–6. http://dx.doi.org/10.4269/ajtmh.13-0406

46. Bogoch II, Brady OJ, Kraemer MU, German M, Creatore MI, Brett S, et al. Potential for Zika virus introduction and transmission in resource-limited countries in Africa and the Asia-Pacific region: a modelling study. Lancet Infect Dis. 2016;16:1237–45. http://dx.doi.org/10.1016/S1473-3099(16)30270-5

47. Centers for Disease Control and Prevention. Guidance for US laboratories testing for Zika virus infection [cited 2017 Jan 22 ]. https://www.cdc.gov/zika/laboratories/lab-guidance.html

48. Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA, Rose L, et al.; MTS. Interim guidance for Interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep. 2016;65:543–6. http://dx.doi.org/10.15585/mmwr.mm6521e1

49. Landry ML, St George K. Laboratory diagnosis of Zika virus infection. Arch Pathol Lab Med. 2017;141:60–7. http://dx.doi.org/10.5858/arpa.2016-0406-SA

50. Wilder-Smith A, Gubler DJ. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science. 2015;350:626–7. http://dx.doi.org/10.1126/science.aaf5036

51. Paulke-Korinek M, Kollaritsch H, Kundi M, Zwai I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015;33:3600–4. http://dx.doi.org/10.1016/j.vaccine.2015.05.037

52. Wittermann C, Izu A, Petri E, Gniel D, Fragapane E. Five year immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2015;92:1–6. http://dx.doi.org/10.4269/ajtmh.13-0406

Address for correspondence: Aravinda M. de Silva and Matthew H. Collins, University of North Carolina School of Medicine, Infectious Diseases, ID Clinic 1st Fl Memorial Hospital, 101 Manning Dr, Chapel Hill, NC 27514, USA; email: desilva@med.unc.edu, matthew.collins@unchealth.unc.edu
Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection

Technical Appendix

Technical Appendix Figure 1. Limited cross-neutralization between Zika virus and DENV. Neutralization activity of immune serum from primary DENV (A), secondary DENV (B), primary Zika virus (C and D), or secondary Zika virus (E, F) against Zika virus H/PF/2013 and 4 serotypes of DENV was determined by
focus-reduction neutralization test (A, B) or plaque reduction neutralization test (C–F) on Vero cells. Neutralizing activity is displayed as a percentage of the number of foci or plaques counted for naïve human serum at each dilution. Results represent the mean of technical replicates per sample and are representative of at least 2 repeats for each serum sample. DENV, dengue virus.

**Technical Appendix Figure 2.** Different Zika virus strains have similar neutralization profiles. Neutralization of 4 Zika virus strains, H/PF/2013 (A), PRVABC59 (B), MR766 (C), and Dakar 41519 (D) by human immune serum was determined by focus-reduction neutralization test on Vero cells.